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TABLE 1. κ Values Reflecting the Concordance Between the 6 Regrade Methods and
the Latest Atlanta Classification
κ (95% CI)
Early Group Late Group Total
Regrade method 1 0.35 (0.18–0.54) 0.44 (0.21–0.66) 0.42 (0.27–0.56)
Regrade method 2 0.13 (−0.02 to 0.26) 0.07 (−0.09 to 0.24) 0.10 (−0.01 to 0.22)
Regrade method 3 0.02 (−0.08 to 0.13) 0.00 (0.00–0.00) −0.01 (−0.06 to 0.05)
Regrade method 4 0.39 (0.22–0.57) 0.44 (0.22–0.66) 0.44 (0.31–0.58)
Regrade method 5 0.17 (0.02–0.34) 0.07 (−0.09 to 0.27) 0.13 (0.01–0.25)
Regrade method 6 0.60 (0.37–0.80) 0.55 (0.34–0.76) 0.59 (0.45–0.72)
Letters to the Editor Pancreas • Volume 49, Number 1, January 2020we used the κ statistic to assess the concor-
dance between the regrade methods, as
shown in Supplemental Table 2 (available
at http://links.lww.com/MPA/A755), and
the revised Atlanta classification.
As shown in Table 1, the κ value of
method 6, which redefined Balthazar grades
A to C as mild AP, Balthazar grade D as
moderately severe AP, and Balthazar grade
E as severe AP (SAP), was 0.59 (95% con-
fidence interval [CI], 0.45–0.72), scaling
the best when compared with other regrade
methods. The κ values of method 6 in sub-
groups for the early group and late group
were 0.60 (95% CI, 0.37–0.80) and 0.55
(95% CI, 0.34–0.76), respectively, indicat-
ing that, whether the CT scan was per-
formed within or after 72 hours after the
onset of symptoms, the groups presented
perfect agreement with the revised Atlanta
classification. Both of the κ values of
method 6 in the early group and late group
present perfect agreement; the reason may
be that most of the included patients had
SAP, which may take less time for pancre-
atic necrosis to develop.
In conclusion, the modified Balthazar
grade, which redefined Balthazar grades A
to C as mild AP, Balthazar grade D as moder-
ately severeAP, andBalthazar gradeE as SAP,
may be a new method to identify the severity
of AP during the early stages. Furthermore,
we can explore whether the new method
can predict the prognosis of AP directly,
which may provide assistance to clinicians.
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Twenty-Five Years of
Increasing Mortality From
Pancreatic Cancer in Portugal
To the Editor:P ancreatic cancer is the seventh leadingcause of cancer death worldwide.1 As
the 5-year survival rate sets around 8.5%,
mortality from pancreatic cancer mostly
overlaps its incidence which has been in-
creasing over the past decades.2–7 In the
United States, incidence increased around
0.95% a year, since 1994.4 In Europe, it is
one of the few tumor types with a consistent
rise inmortality.8 Common risk factors, such
as obesity, smoking habits, and dietary pat-
terns may be driving this trend, given that
higher human development indexes appear
to associatewith pancreatic cancer mortality.4,7© 2019
 2019 Wolters Kluwer Health, Inc. All rights reWe conducted an epidemiological anal-
ysis on pancreatic cancer mortality trends in
Portugal over the past 25 years. Using the
Portuguese National Statistical Institute pub-
lic database, we identified deaths attributed
to malignant pancreatic cancer (ICD10-C25;
ICD9/8–157) on official death certificates is-
sued between 1991 and 2015. Demographic
variables analyzed included sex, age at time
of death, and geographic area of residency.
Age-adjusted mortality rates (AAMR) were
calculated adjusting for age distribution ac-
cording to the 2013 revised European stan-
dard population. Mortality trends were
calculated using the Jointpoint Regression
software 4.4.0.0 (Statistical Research
and Applications Branch, National Cancer
Institute, Bethesda,Md) tracing annual per-
cent changes (APC) and average APCs
(AAPC) from a logistic regression model. A
mortality forecast was done through a univari-
ate Autoregressive Integrated Moving Aver-
age (ARIMA) model using IBM SPSS
Statistics v24 (IBM Corp, Armonk, NY).
Our findings show that pancreatic
cancer-associated deaths doubled from 701
deaths in 1991 to 1415 in 2015, reflecting
a mean annual increase of around 3%
(APC, 2.85; 95% confidence interval [CI],
2.64–3.06; P < 0.001). The AAMR also in-
creased throughout this period (AAPC,
0.91%; 95% CI, 0.57–1.26; P < 0.001)
reaching a maximum of 12.79 per 100,000
habitants by 2015. Remarkably, the rate of
increase was three times higher in the last
half (APC2004–2015, 1.56%; 95% CI,
1.03–2.14; P < 0.001) as compared with
the first half (APC1991–2004, 0.37%; 95%
CI, −0.14 to 0.87; P = 0.145).
Age analysis confirmed a negligible
mortality (0.8% of deaths) below the age
of 40 years. The 75 to 79 years age group
recorded the highest mean AAMR, and al-
though it increased across all age groups
above 45 years, the most noteworthy rise,
nearly twice that of the remaining age
groups, was registered within the 50 to
54 years age group (APC, 1.61; 95% CI,
0.65–2.59; P = 0.002).
As expected, AAMR was higher in
males (mean [standard deviation {SD}],
14.12 [1.24] vs 8.88 [0.74]; P < 0.001)
who showed a peak mortality at the 70 to
74 years age group (AAMR, 2.47 [SD,
0.34]) and a nonlinear increase (AAPC,
0.88; 95% CI, 0.36–1.39; P = 0.001) with
an APC of around 2% a year since 2004
(APC2004–2015, 2.02; 95% CI, 1.22–2.83;
P < 0.001). In contrast, female mortality
was higher within the ≥85 age group
(AAMR = 1.75 [SD, 0.25]) and AAMR in-
creased linearly (AAPC, 0.90; 95% CI,
0.59–1.21; P < 0.001).
There were also some interesting geo-
graphical asymmetries in pancreatic cancerWolters Kluwer Health, Inc. All rights reserved.
served.
FIGURE 1. Prediction of the pancreatic cancer-associated mortality for the Portuguese population. Fitted by an ARIMA (4, 1, 0) model.
Pancreas • Volume 49, Number 1, January 2020 Letters to the Editormortality. TheAzores Islands (AAMR, 26.27
[SD, 4.86]) and Alentejo (AAMR, 19.29
[SD, 4.48]) displayed the highest AAMRs.
Alongside Madeira Island, these regions
also have the highest mortality increase
over the study period, ranging from 2.52%
a year for Alentejo (AAPC, 2.52; 95% CI,
1.89–3.16; P < 0.001) to 1.53% for Azores
(AAPC, 1.53; 95%CI, 0.59–2.48,P = 0.003).
All the remaining regions showed an AAPC
below 1%.
Finally, including the data from 1991
until 2017, we forecasted the annual num-
ber of deaths for the next 20 years. By
2035 annual deaths from pancreatic cancer
should surpass 2000 (n = 2137; 95% CI,
1862–2413), reflecting a 51% increase (Fig. 1).
Summing up, from 1991 to 2015, an-
nual deaths from pancreatic cancer dou-
bled, crude mortality rates increased by
67.5% (AAPC, 2.7%), and AAMRs grew
an impressive 22.8% (AAPC, 0.91%). These
findings match the ones reported for other
developed countries.3,7 The most plausible
explanation appears to be the increasing
prevalence of associated risk factors.4,6 In-
deed, Alentejo and Azores show the highest
prevalence of active smokers and overweight
individuals in all country.9 This might explain
why, despite accounting for only 9.4% of the
Portuguese population, these regions recorded
both a mean AAMR and a growth rate that
was nearly twice the rest of the population.
Another meaningful finding was a
higher rate of AAMR increase among the
50 to 54 years age group. This is roughly
15 years below the age of peak incidence,
suggesting that we may be facing a change
toward a younger age of incidence.
Lastly, if our prediction is correct, we
will face a 51% increase in annual deaths
during the next 2 decades. As each death
by pancreatic cancer results in a mean loss
of 11 years of healthy life expectancy,10 it
appears undeniable that we need to raise a© 2019 Wolters Kluwer Health, Inc. All rights reser
Copyright special awareness concerning pancreatic can-
cer in the near future.
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